- "We believe that the ASCEND trial of pirfenidone for idiopathic pulmonary fibrosis will be successful when the data is top lined Q2 2014," Summer Street's Bart Classen says, in a bullish note on shares of InterMune (ITMN +0.3%) which he says could rise another 20% in Q1.
- "The trial is similar to three previous Phase 3 trials but is only 52 weeks in duration," Classen notes, before adding that "all previous trials were statistically significant in the 48-52 week range."
- As an aside, Summer Street doesn't think Boehringer Ingelheim’s nintedanib will succeed in IPF.
Summer Street sees further upside for InterMune
Dec 30 2013, 14:37 ET